Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | EP300 | Q09472 | 1/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.45 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.45 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2148941 | 0.98 | PKM (0.96) | PKMHTTLMNAKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL1651218 | 0.96 | PKM (0.92) | PKMHTTLMNAKDM4EMAPT | |
| SCHEMBL11583446 | 0.83 | PKM (0.70) | PKMHTTLMNAKDM4EMAPT | |
| SCHEMBL31634598 | 0.79 | PKM (0.65) | PKMHTTLMNAKDM4EMAPT | |
| SCHEMBL7191579 | 0.79 | PKM (0.65) | PKMHTTLMNAKDM4EMAPT | |
| SCHEMBL10579123 | 0.79 | HTT (0.71) | PKMHTTLMNAKDM4EMAPT | |
| SCHEMBL4630376 | 0.79 | HTT (0.71) | PKMHTTLMNAKDM4EMAPT | |
| SCHEMBL352532 | 0.77 | PKM (0.63) | PKMHTTLMNAKDM4EMAPT | |
| SCHEMBL31517208 | 0.77 | PKM (0.63) | PKMHTTLMNAKDM4EMAPT | |
| SCHEMBL10712402 | 0.77 | PKM (0.63) | PKMHTTLMNAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345289-A1 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | EPIZON INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250339386-A1 | VITAMIN K2 FOR USE IN TREATMENT OF CORONARY ARTERY CALCIFICATION | REGION SYDDANMARK (DK) | 2025-11-06 | — | — | US | claimed |
| EP-3938040-B1 | VITAMIN K2 IN COMBINATION WITH ANTICOAGULANTS FOR USE IN TREATING MUSCLE SORENESS | LESAFFRE & CIE (FR) | 2025-05-21 | — | — | EP | claimed |
| EP-4531825-A1 | VITAMIN K2 FOR USE IN TREATMENT OF CORONARY ARTERY CALCIFICATION | Region Syddanmark (DK) | 2025-04-09 | — | — | EP | claimed |
| WO-2025011276-A1 | GLYCOPEPTIDE MOLECULE | 粤港澳大湾区精准医学研究院(广州) | 2025-01-16 | — | — | WO | claimed |
| CN-119306802-A | Glycopeptide molecule | 粤港澳大湾区精准医学研究院(广州) | 2025-01-14 | — | — | CN | claimed |
| CN-119300813-A | Vitamin K2 for the treatment of Coronary Artery Calcification (CAC) | 南丹麦大区 | 2025-01-10 | — | — | CN | claimed |
| CN-118926753-A | Modularized construction method of dry moving bed desulfurizing tower | 中化二建集团有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20240307321-A1 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | Epizon Pharma, Inc. (US) | 2024-09-19 | — | — | US | claimed |
| WO-2024177973-A1 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | Epizon Pharma, Inc. (US) | 2024-08-29 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-11289345-B2 | Heat releasing semiconductor chip package and method for manufacturing the same | MAGNACHIP SEMICONDUCTOR, LTD. (KR) | 2022-03-29 | — | — | US | claimed |
| CN-114231554-A | Vitamin k2Biosynthesis method of series products | 安徽工程大学 | 2022-03-25 | — | — | CN | claimed |
| US-20150283290-A1 | STERILIZED COMPOSITIONS OF CYANOACRYLATE MONOMERS AND NAPHTHOQUINONE 2,3-OXIDES | ADHEZION BIOMEDICAL, LLC (US) | 2015-10-08 | — | — | US | claimed |
| CN-103025338-B | Composition for improving condition of skin | MEIJI CO LTD | 2015-01-28 | — | — | CN | claimed |
| CN-103025338-A | Composition for improving condition of skin | MEIJI CO LTD | 2013-04-03 | — | — | CN | claimed |
| US-20090281187-A1 | ANTI-ALLERGIC AGENT | MEIJI DAIRIES CORP (JP) | 2009-11-12 | — | — | US | claimed |
| CN-101247800-A | Antiallergic agent | MEIJI DAIRIES CORP (JP) | 2008-08-20 | — | — | CN | claimed |
| EP-1946752-A1 | ANTI-ALLERGIC AGENT | Meiji Dairies Corporation (JP) | 2008-07-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307321-A1 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | PROC, NDUFS6, NDUFS3 | PKM 596/4885HTT 2863/4885LMNA 639/4885 |
| US-20250345289-A1 | NANO-PARTICLES OF MENAQUINONE AND METHODS OF TREATMENT | PROC, NDUFS6, NDUFS3 | PKM 596/4885HTT 2863/4885LMNA 639/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PKM 2064/4885HTT 786/4885LMNA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.